Biogen Inc (BIIB) Falls 5.27% for February 08

Equities Staff |

One of the S&P 500’s big losers for Monday February 08 was Biogen Inc (BIIB). The company’s stock fell 5.27% to $249.95 on volume of 2.17 million shares.

The stock opened the day at 260.45 and traded between a low of $248.16 and a high of $260.45. The stock finished the day down $13.91 per share. Biogen Inc has an average daily volume of 2.39 million and a total float of 218.67 million shares. The 50-day SMA for Biogen Inc is $283.89 and its 200-day SMA is $325.29. The high for the stock over the last 52 weeks is $480.18 and the low is $254.00.

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Biogen Inc is centered in Cambridge, MA, and has 7,350 employees. Today’s trading day leaves the company with a market cap of $54.66 billion. The company has a P/S ratio of n/a, P/B ratio of 5.83, and a 28.5.

For a complete fundamental analysis analysis of Biogen Inc, check out Equities.com’s Stock Valuation Analysis report for BIIB. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…